Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis)

被引:27
|
作者
Yoshida, Atsushi [1 ,2 ]
Watanabe, Meri [2 ]
Okubo, Akira [2 ,3 ]
Kawashima, Hidetoshi [2 ]
机构
[1] JFCR, Div Ophthalmol, Canc Inst Hosp, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan
[2] Jichi Med Univ, Dept Ophthalmol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan
[3] Okubo Eye Clin, 1137-4 Hiramatsu Honcho, Utsunomiya, Tochigi 3210932, Japan
关键词
Scleritis; Episcleritis; Rheumatoid arthritis; Anti-neutrophil cytoplasmic antibody (ANCA); ANCA-associated vasculitis; RITUXIMAB; EPISCLERITIS; FEATURES;
D O I
10.1007/s10384-019-00674-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose We evaluated patient profiles, clinical features, associated systemic diseases, treatment modalities, and ocular complications in cases of scleritis and episcleritis. Study design Retrospective. Methods Clinical data of 128 patients referred to the ophthalmology clinic at Jichi Medical University Hospital during the 4-year period from April 2011 to March 2015, and diagnosed with scleritis or episcleritis were examined. Gender, average onset age, unilateral or bilateral manifestation, classification type, associated systemic diseases, and treatments were retrospectively investigated. Results The cohort consisted of 57 men and 71 women. Average onset age was 54.3 +/- 17.4 years. Diffuse anterior scleritis was the most common type. It was noted in 43 (32.8%) patients, followed by episcleritis in 35 (27.3%), nodular anterior scleritis in 23 (18.0%), necrotizing anterior scleritis in 22 (17.2%), and posterior scleritis in 6 (4.7%). Eighteen (81.8%) of 22 patients with necrotizing anterior scleritis required some type of systemic medication, including corticosteroid, cyclophosphamide, cyclosporine, azathioprine, methotrexate, or rituximab administration. Forty (31.3%) had associated systemic diseases, which included 10 with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and 8 with rheumatoid arthritis (RA). Patients with ANCA-associated vasculitis had a tendency to develop scleritis first and had significantly worse visual prognoses compared to those with RA. Conclusions Approximately 30% of the patients with scleritis and episcleritis had complications involving systemic diseases, including ten patients with ANCA-associated vasculitis and 8 with RA. ANCA-associated vasculitis was more often diagnosed after scleritis and patients suffered poorer visual prognoses than those with RA.
引用
收藏
页码:417 / 424
页数:8
相关论文
共 50 条
  • [1] Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases (anti-neutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis)
    Atsushi Yoshida
    Meri Watanabe
    Akira Okubo
    Hidetoshi Kawashima
    Japanese Journal of Ophthalmology, 2019, 63 : 417 - 424
  • [2] Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis
    Haiting Wu
    Yiyun Lu
    Rongrong Hu
    Wei Ye
    Yubing Wen
    Jianfang Cai
    Hang Li
    Xuemei Li
    BMC Nephrology, 23
  • [3] Anti-neutrophil cytoplasmic antibody associated vasculitis in patients with rheumatoid arthritis
    Wu, Haiting
    Lu, Yiyun
    Hu, Rongrong
    Ye, Wei
    Wen, Yubing
    Cai, Jianfang
    Li, Hang
    Li, Xuemei
    BMC NEPHROLOGY, 2022, 23 (01)
  • [4] Anti-neutrophil cytoplasmic antibody-associated systemic vasculitis: nature or nurture?
    Gatenby, P. A.
    INTERNAL MEDICINE JOURNAL, 2012, 42 (04) : 351 - 359
  • [5] Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis
    Hruskova, Zdenka
    Geetha, Duvuru
    Tesar, Vladimir
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 : i159 - i163
  • [6] Anti-neutrophil cytoplasmic antibody-associated vasculitis. Clinical aspects and treatment
    Virginia Paolini, Maria
    Pablo Ruffino, Juan
    Fernandez Romero, Diego S.
    MEDICINA-BUENOS AIRES, 2013, 73 (02) : 119 - 126
  • [7] Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis
    Basu, Neil
    McClean, Andrew
    Harper, Lorraine
    Amft, Esther N.
    Dhaun, Neeraj
    Luqmani, Raashid A.
    Little, Mark A.
    Jayne, David R. W.
    Flossmann, Oliver
    McLaren, John
    Kumar, Vinod
    Erwig, Lars P.
    Reid, David M.
    Macfarlane, Gary J.
    Jones, Gareth T.
    RHEUMATOLOGY, 2014, 53 (05) : 953 - 956
  • [8] A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis
    Moura, Marta Casal
    Branco, Carolina
    Martins-Martinho, Joana
    Ferraro, Jose Luis
    Berti, Alvise
    Nogueira, Estela
    Ponte, Cristina
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [9] Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis
    Weng, Cheng-Hua
    Liu, Zhi-Chun
    CHINESE MEDICAL JOURNAL, 2019, 132 (23) : 2848 - 2855
  • [10] Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
    Rhee, Eugene P.
    Laliberte, Karen A.
    Niles, John L.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (08): : 1394 - 1400